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bstract
ackground: Due to the differences in the oncogenic activity of human papillomaviruses (HPV), it is clinically important to accurately
dentify HPV types in a simple and time effective manner.
bjectives: We aimed at developing a straightforward and cost-effective assay to individually identify all mucosal HPVs, based on the
mplification of L1 gene using MY09/11 primers, and subsequent restriction fragment length polymorphism (RFLP) analysis.
tudy design: We made use of bioinformatic tools to analyze all published DNA sequences of 49 mucosal HPV types for PstI, HaeIII, DdeI
nd RsaI restriction sites. Based on the RFLP patterns, we have designed an original genotyping algorithm.
esults: Each HPV type presented a distinct RFLP pattern, which was visually distinguishable on polyacrylamide gels. A set of 27 pre-
elected patient samples of known HPV types was confirmed positive for the same HPV type using this RFLP assay. Furthermore, in a
andom and blind HPV typing experiment performed in 30 untyped clinical samples, RFLP data consistently matched DNA sequencing
esults.
onclusions: Our polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, using 4 restriction enzymes
PstI, HaeIII, DdeI, RsaI) and an original genotyping algorithm, allows discrimination of all individual mucosal HPV types in single infections,
nd even detection of multiple infections. This assay gives complementary information to commercially available methods, and may also be
nancially advantageous, particularly when financial resources are scarce.
2007 Elsevier B.V. All rights reserved.
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1. Introduction
Cervical cancer is the second most common cancer in
omen worldwide, and the most common cancer in most
eveloping countries (Moore, 2006). Epidemiologic studies
∗ Corresponding author at: Molecular Pathology Laboratory, Portuguese
nstitute for Oncology at Coimbra, EPE, Avenida Bissaya Barreto 98, 3000-
75 Coimbra, Portugal. Tel.: +351 239400200x2272; fax: +351 239484317.
E-mail addresses: rui.jorge.nobre@gmail.com (R.J. Nobre),
uispa@ci.uc.pt (L.P. de Almeida), tmartins@ipocoimbra.min-saude.pt
T.C. Martins).
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oi:10.1016/j.jcv.2007.11.021ave established that certain types of human papillomavirus
HPV) are the main cause of cervical cancer (Mun˜oz et al.,
992; Walboomers et al., 1999; Bosch et al., 2002). HPVs are
heterogeneous group of double stranded, non-enveloped
NA viruses of the Papillomaviridae family (de Villiers et
l., 2004). At present, more than 100 HPV types have been
dentified. However, only HPVs of the Alpha-papillomavirus
enus, which includes mucosal and cutaneous types, infect
he anogenital epithelium (de Villiers et al., 2004). The
ucosal HPV types of this genus have been divided into four
roups based on their oncogenic activity: high-risk types
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59),
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Table 1
Mucosal HPV types considered for typing (Family Papillomaviridae, genus
Alpha-papillomavirus)
Species HPV types
1 32, 42
3 61, 62, 72, 81, 83, 84, 86, 87, 89, 102
5 26, 51, 69, 82
6 30, 53, 56, 66
7 18, 39, 45, 59, 68, 70, 85, 97
8 40, 43, 91
9 16, 31, 33, 35, 52, 58, 67
10 6, 11, 13, 44, 74
11 34, 73
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robable high-risk types (26, 53, 66, 68, 73, 82), low-risk
ypes (6, 11, 13, 40, 42, 43, 44, 54, 61, 70, 72, 81 and 89)
nd types of undetermined-risk (30, 32, 34, 62, 67, 69, 71,
4, 83, 84, 85, 86, 87, 90, 91) (Mun˜oz et al., 2006). Due to
ifferences in oncogenic activity, it is clinically important to
etect HPV infection and to accurately identify HPV types
n a simple and time effective manner.
In cervical screening programs, HPV-DNA is usually
etected by a non-radioactive signal amplification method,
he Hybrid Capture System II (Digene Diagnostics) (Lorincz,
996; Bozzetti et al., 2000). This methodology allows the
etection of 13 probable/high-risk and 5 low-risk types using
wo different cocktail RNA probes, in two separate reac-
ions. Following approval by Food and Drug Administration
FDA), Hybrid Capture System II became the standard pro-
edure for HPV DNA detection. However, Hybrid Capture
ystem II has some important limitations, as it does not
rovide information about the specific type of HPV that is
etected, giving a positive result when at least one of the
8 types is present. Furthermore, it is less sensitive than
CR (Smits et al., 1995; Cope et al., 1997) and the cross-
eactivity of the two cocktail probes reduces the clinical
elevance of a positive result (Castle et al., 2002; Poljak et
l., 2002). Nucleic acid amplification has been developed
o increase the sensitivity and the specificity of HPV-DNA
etection. The majority of protocols use GP5+/6+ consen-
us primers (Van den Brule et al., 1990; de Roda Husman
t al., 1997) or MY09/11 degenerate primers (Manos et
l., 1989). Both sets of primers are directed to a highly
onserved region of the HPV L1 gene and are potentially
apable of detecting a large number of mucosal HPV types
n a single PCR reaction (Hildesheim et al., 1994). After
PV detection using consensus primers, PCR amplimers
an be analyzed by several HPV typing assays: restriction
ragment length polymorphism (RFLP), reverse hybridiza-
ion analysis, microarray platforms or sequencing. PCR
sing consensus primers with subsequent restriction frag-
ent length polymorphism analysis (PCR-RFLP) has been
emonstrated to be a sensitive and a financially advanta-
eous methodology to detect and characterize HPV-DNA
n clinical specimens (Lungu et al., 1992). However, the
CR-RFLP techniques previously described have some lim-
tations: (a) they do not allow the genotyping of all high-risk
PV types (Pizzighella et al., 1995; Patti et al., 2002; Naqvi
t al., 2004); (b) they often make use of a large number of
estriction enzymes (Bernard et al., 1994; Astori et al., 1997);
c) they are ineffective or time consuming with regards to
FLP-pattern analysis on polyacrylamide gels and to identi-
cation of given HPV types (Bernard et al., 1994; Astori et
l., 1997).
In this work we have developed an easy, rapid and cost-
ffective PCR-RFLP assay to identify all known mucosal
PVs, based on the amplification of a fragment of the L1
ene using MY09/11 primers and subsequent RFLP anal-
sis with four restriction enzymes: PstI, HaeIII, DdeI and
saI.
T
T
t
p3 54
4 90
5 71, 106
. Materials and methods
.1. HPV DNA sequences and restriction site “in silico”
nalysis
All published DNA sequences of mucosal HPV types
Table 1) were obtained from the GenBank database
http://www.ncbi.nlm.nih.gov/Genbank/). These sequences
ere subsequently aligned using the “Alignment tool” of
LC Free Workbench program, version 3.2 (CLC bio,
enmark) and DNA segments of the L1 gene that are
racketed by the MY09/11 primers (MY09/11 amplicons)
ere selected and compiled in a file. A second file was
reated, which included the selected restriction enzymes
PstI, HaeIII, DdeI, RsaI). Finally, using the “Restriction
ite analysis tool” of CLC Free Workbench program, the
nformation from both files was crossed in order to pre-
ict the product sizes of each MY-amplicon restriction
eaction.
.2. HPV detection in clinical samples
A set of pre-selected clinical samples, in which 27 dif-
erent mucosal HPV types had been previously identified
y PCR and DNA sequencing (HPV 6, 11, 16, 18, 31, 33,
4, 35, 39, 44, 45, 52, 53, 56, 58, 59, 61, 62, 66, 67, 70,
1, 73, 81, 83, 84, and 102) and a representative collec-
ion of 30 untyped clinical samples (10 normal samples,
0 low-grade squamous intraepithelial lesions, 5 high-grade
quamous intraepithelial lesions and 5 invasive squamous
ervical carcinoma) were obtained from the ongoing cer-
ical cancer screening program of the Portuguese Institute
or Oncology at Coimbra (IPOCFG, EPE). Cervical samples
ere collected in PreservCyt (Cytyc Corporation, Boxbor-
ugh, MA, USA), a liquid cytology medium, and centrifuged
t 4500 rpm for 15 min. The pelleted cells were lysed in a
ris-buffered solution (0.3 M NaCl, 10 mM EDTA, 10 mM
ris pH 7.5), containing 0.5% SDS and 0.5g/l pro-
einase K, at 56 ◦C. The DNA was purified by standard
henol/chloroform extraction and ethanol precipitation. HPV
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NA was detected by PCR using the degenerate consen-
us primers MY09 (5′-CGTCCMARRGGAWACTGATC-3′)
nd MY11 (5′-CMCAGGGWCATAAYAATGG-3′), which
mplify a region of 449–458 nucleotides (depending on
PV type) of the highly conserved L1 ORF (Manos et
l., 1989). Each PCR amplification was carried out with
0–100 ng of template DNA in 1× PCR Buffer (Biotools,
adrid, Spain), containing 1.5 mM MgCl2, 12.5 pmol of each
rimer, 200M of each deoxynucleotide triphosphate and
unit of Taq DNA polymerase (Biotools, Madrid, Spain).
hermal cycling was performed in a Perkin-Elmer 9600
PerkinElmer, MA, USA) as follows: denaturation of DNA
emplate at 95 ◦C for 4 min, followed by 35 cycles of 94 ◦C
or 30 sec, 56 ◦C for 30 sec, and 72 ◦C for 30 sec, and a final
xtension step at 72 ◦C for 8 min. To check the integrity
f the DNA extracted from the specimens, a region of
01 base pairs of the cellular -globin gene was amplified
sing primers Beta1 (5′-TCAACCCTACAGTCACCCAT-3′)
nd Beta2 (5′-CTAACAATTACGAACAGCAATGAG-3′).
he PCR conditions were the same as described for HPV
etection. All PCRs were carried out under conditions that
inimize sample cross-contamination. DNA from HeLa and
aSki cell lines was used as positive control. A negative con-
rol containing all PCR reagents, except DNA, was added
o monitor contamination. In order to verify the amplifica-
ion efficiency and the absence of unspecific products, the
mplified DNA was analyzed in a horizontal 2% agarose
el.
.3. HPV typing by RFLP (PstI, HaeIII, RsaI, DdeI)
HPV-positive cases were typed by RFLP analysis. Each
estriction reaction was performed separately in a final vol-
me of 20l, using 1g of MY09/11 PCR product, 2l of
0× recommended restriction buffer, and 10 units of the fol-
owing restriction endonucleases: PstI (Qbiogene, CA, USA),
aeIII (Fermentas Inc., Canada), DdeI (Qbiogene, CA, USA)
nd RsaI (Fermentas Inc., Canada), according to the manu-
acturers’ instructions. Reactions took place at 37 ◦C for 1 h.
igested products were electrophoretically separated on 10%
olyacrylamide gels, in the presence of 25 bp and 50 bp DNA
olecular weight markers (Invitrogen, Carlsbad, CA, USA).
els were stained with Gelstar (Cambrex Bio Science Rock-
and, Inc., ME, USA) for 15 min and patterns were visualized
sing a Versa Doc Imaging System (Bio-Rad, Hercules, CA,
SA).
.4. Validation of RFLP restriction reaction
To test the efficacy of each enzyme and to avoid the
isidentification of types due to partial digestion, an addi-
ional restriction reaction was performed, in which MY09/11
CR products and a control DNA (PCR product of -
lobin fragment amplification, obtained in 2.2) were digested
ogether. Each restriction reaction was performed in a final
olume of 20l, using 1g of MY09/11 PCR product, 1g
e
i
d
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f Beta1/2 amplicon, 2l of 10× recommended restriction
uffer, and 20 units of each restriction endonuclease, accord-
ng to the conditions described in 2.3.
.5. Confirmation of RFLP data using sequencing
All MY-PCR products obtained in Section 2.2 were
equenced to confirm the RFLP results. The PCR products
ere purified from agarose gel using a PCR clean-up Gel
xtraction Kit (NucleoSpin® Extract II, Macherey-Nagel,
ermany) and cloned. At least five fragments of each
mplicon were sequenced. Forward and reverse sequencing
eactions were carried out using 20 ng of template DNA from
CR amplimers and 20M of the MY09 and MY11 primers,
espectively. Automated DNA sequencing was performed
y MWG DNA Biotech Company (Germany). Sequences
btained were compared with all sequences available in Gen-
ank database. HPV type was identified based on >98%
equence homology over 449–458 nucleotides.
. Results
.1. HPV DNA sequences and restriction site “in silico”
nalysis
A total of 296 different DNA sequences of the L1 gene
HPV variants), corresponding to 49 mucosal HPV types,
ere obtained from the GenBank database. The in silico
nalysis of their MY09/11 amplicons for PstI, HaeIII, DdeI
nd RsaI restriction sites defined 74 different sets of RFLP
atterns: 49 corresponded to reference HPV types, 2 cor-
esponded to HPV subtypes (HPV 55 and HPV 64), and
3 corresponded to HPV variants, which had an altered
FLP-pattern with regards to their respective reference type
Table 2). Each type presented specific sets of RFLP pat-
erns, which were not shared with any other HPV type.
ll HPV types were clearly identifiable by visual dis-
rimination on 10 % polyacrylamide gels, except for one
articular situation (case of HPV 85 and b variant of HPV
2), in which the size of the restriction fragments dif-
ered only by 9 bp. In this specific case, the problem can
e solved using a more concentrated polyacrylamide gel,
sing type-specific PCR or by sequencing this MY09/11
mplicon.
.2. The algorithm for mucosal HPV typing
To analyze the RFLP-patterns, we developed a novel
PV genotyping algorithm (Fig. 1). The algorithm design
as based in: a) the 74 sets of RFLP-patterns obtained forach mucosal HPV type, subtype and variant, as described
n Table 2; and b) the fact that each restriction enzyme
oes not cut some of MY09/11 amplicons, as described in
able 3.
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Table 2
RFLP fragment sizes and GenBank accession numbers of sequences used as representative of the 49 mucosal HPV types
HPV type GenBank sequence MY PCR amplicon (bp) RFLP fragment sizes (bp)
PstI HaeIII DdeI RsaI
6 S73503 449 449 217, 124, 108 382, 67 161, 149, 72, 67
11 M14119 449 242, 207 217, 124, 108 447, 2 216, 135, 72, 26
13 X62843 455 242, 213 204, 127, 124 326, 67, 62 175, 135, 73, 72
16 U89348 452 216, 210, 26 444, 8 452 310, 72, 70
18 X05015 455 242, 213 455 432, 23 135, 125, 85, 72, 38
18a U45891 455 242, 213 455 432, 23 260, 85, 72, 38
26 X74472 455 353, 102 455 455 365, 72, 18
30 X74474 449 242, 207 232, 217 291, 158 449
31 AJ831566 452 216, 210, 26 328, 124 283, 167, 2 380, 72
31a DQ241373 452 216, 210, 26 328, 124 283, 90, 77, 2 380, 72
32 X74475 449 449 317, 124, 8 320, 108, 21 216, 161, 72
33 U45896 449 242, 207 449 320, 77, 52 236, 102, 72, 39
34 X74476 458 253, 179, 26 334, 124 211, 151, 88, 8 186, 161, 96, 15
35 U45898 452 426, 26 261, 180, 8, 3 294, 135, 23 177, 161, 72, 42
39 M62849 455 330, 125 455 324, 131 260, 123, 72
40 X74478 455 455 447, 8 297, 158 365, 90
42 M73236 449 449 449 341, 108 242, 135, 72
43 AJ620205 449 273, 176 331, 118 447, 2 332, 72, 45
44 U12493 455 455 215, 124, 108, 8 297, 112, 46 222, 161, 72
45 X74479 455 242, 213 447, 8 324, 131 338, 72, 45
45a U45914 455 242, 213 447, 8 324, 131 237, 101, 72, 45
45b U45907 455 242, 213 447, 8 324, 131 203, 180, 72
45c U45911 455 242, 213 447, 8 324, 131 180, 158, 72, 45
51 U45917 452 452 379, 73 362, 90 380, 72
52 U45920 449 423, 26 258, 183, 8 357, 92 449
52a U45919 449 423, 26 258, 183, 8 246, 107, 96 449
52b U45918 449 423, 26 258, 183, 8 449 449
53 X74482 449 449 232, 217 206, 158, 85 449
53a DQ241374 449 449 232, 217 243, 206 449
54 U12501 452 452 217, 127, 108 452 138, 125, 117, 72
54a AF436129 452 245, 207 217, 127, 108 452 138, 125, 117, 72
55* U12494 455 455 215, 124, 108, 8 112, 111, 101, 85, 46 165, 161, 72, 57
56 X74483 449 242, 207 275, 166, 8 307, 142 310, 72, 49, 18
58 U45927 449 216, 207, 26 449 348, 101 306, 111, 32
58a U45929 449 216, 207, 26 449 449 306, 143
58b DQ241375 449 216, 210, 23 449 449 304, 111, 34
59 X77858 455 429, 26 399, 56 455 455
59a U45933 455 429, 26 455 455 455
61 U12500 455 455 212, 211, 24, 8 455 185, 180, 72, 18
62 U12499 449 341, 108 232, 217 449 359, 72, 18
64* U12495 458 432, 26 334, 124 211, 151, 87, 9 186, 161, 72, 39
66 U12498 449 207, 150, 66, 26 449 291, 158 449
66a DQ344527 449 207, 150, 66, 26 441, 8 291, 128, 30 449
66b DQ486474 449 207, 150, 66, 26 449 291, 158 377, 72
67 U12492 449 423, 26 266, 183 307, 92, 50 310, 72, 67
68 U45934 455 455 455 455 260, 85, 72, 38
68a AJ831567 455 455 386, 69 455 260, 85, 72, 38
69 U12497 455 455 223, 183, 49 455 365, 72, 18
70 U12476 455 242, 213 232, 117, 106 455 231, 123, 72, 29
70a U22461 455 242, 213 232, 117, 106 297, 158 231, 123, 72, 29
70b AF538717 455 242, 213 232, 223 455 231, 123, 72, 29
70c U21941 455 455 232, 117, 106 455 231, 123, 72, 29
71 AY330622 452 360, 92 217, 127, 108 320, 132 380, 72
72 U12477 455 455 220, 211, 24 300, 155 365, 72, 18
73 U12491 458 432, 26 458 243, 215 201, 161, 96
74 AF436130 455 455 218, 180, 49, 8 215, 126, 114 165, 158, 72, 60
74a Y12221 455 455 455 455 222, 161, 72
74b U40822 455 455 232, 215, 8 243, 212 222, 161, 72
81 AJ620209 452 341, 111 127, 121, 108, 96 452 452
82 AB027021 455 455 447, 8 455 310, 73, 72
82a AF293961 455 455 447, 8 243, 212 383, 72
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Table 2 (Continued )
HPV type GenBank sequence MY PCR amplicon (bp) RFLP fragment sizes (bp)
PstI HaeIII DdeI RsaI
82b U12483 455 455 455 288, 167 383, 72
83 U12489 452 317, 135 383, 69 452 380, 72
83a LVX82 452 452 383, 69 452 380, 72
84 U12490 452 452 346, 106 220, 142, 90 310, 142
85 AF131950 455 455 455 297, 158 383, 72
86 AF349909 452 317, 135 343, 106, 3 310, 125, 17 380, 72
87 AF400628 452 351, 101 232, 209, 8, 3 362, 90 380, 72
89 U12478 452 452 325, 127 246, 152, 54 380, 72
90 AF042837 449 449 232, 209, 8 449 310, 139
91 AF070938 455 455 455 357, 98 455
97 DQ080080 455 242, 213 447, 8 362, 93 135, 125, 123, 72
102 DQ080083 452 359, 93 166, 121, 96, 69 452 452
106 DQ080082 452 452 209, 127, 108, 8 452 452
Restriction fragments larger than 40 bp are in bold. Fragments under this size are not considered for discrimination of HPV types, because they are not visualized
with good resolution in polyacrylamide or agarose gels. HPV 55* is a subtype of HPV 44, and HPV 64* is a subtype of HPV 34, as reported by de Villiers et
al. (2004). The superscript letters (a–c) show HPV variants that have an altered RFLP-pattern with regards to their respective reference HPV type.
Table 3
MY09/11 amplicons that are not cut by PstI, HaeIII, DdeI and RsaI restriction enzymes
Restriction enzyme Restriction site not present in MY09/11 amplicons of HPVs
PstI HPV 6, 32, 40, 42, 44, 51, 53, 53a, 54, 55, 61, 68, 68a, 69, 70c, 72, 74, 74a, 74b, 82, 82a, 82b, 83a, 84, 85, 89, 90, 91, 106
HaeIII HPV 18, 18a, 26, 33, 39, 42, 58, 58a, 58b, 59a, 66, 66b, 68, 73, 74a, 82b, 85, 91
D , 59a, 61
R 66, 66a
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4deI HPV 16, 26, 52b, 54, 54a, 58a, 58b, 59
saI HPV 30, 52, 52a, 52b, 53, 53a, 59, 59a,
he superscript letters (a–c) show HPV variants that have an altered RFLP
.3. Evaluation of RFLP restriction efficacy
Since digestion can be partial or fail due to several fac-
ors, we have designed a strategy, which was done in parallel
o the HPV genotyping, to avoid misidentification of types,
ased in the co-digestion of MY09/11 amplicon with a control
NA. For that purpose, we have designed a pair of primers
hat target a region of -globin gene (Beta1/2 amplicon),
hich is cleaved by the whole spectrum of selected restriction
nzymes when optimal conditions are achieved, originating
he following restriction fragments: PstI: 322 bp + 179 bp;
aeIII: 279 bp + 222 bp; DdeI: 271 bp + 198 bp + 32 bp; RsaI:
51 bp + 210 bp + 40 (Fig. 2). The size of these fragments
oes not coincide with any of the fragments listed in Table 2.
.4. Evaluation of HPV typing approach in clinical
amples
To confirm the reliability of this PCR-RFLP based
ethodology and the applicability of the HPV typing algo-
ithm, two different experiments were performed. The first
tudy was carried out, in a blind fashion, on pre-selected HPV-
ositive clinical samples, in which 27 different mucosal HPV
ypes had been previously identified by PCR with MY09/11
rimers and DNA sequencing (HPV 6, 11, 16, 18, 31, 33, 34,
5, 39, 44, 45, 52, 53, 56, 58, 59, 61, 62, 66, 67, 70, 71, 73,
1, 83, 84, and 102). In all samples, PCR-RFLP data consis-
ently matched the DNA sequencing results. Fig. 3 shows the
FLP patterns of some HPV types (HPV 16, 58 and 102).
i
H
a
a, 62, 68, 68a, 69, 70, 70b, 70c, 74a, 81, 82, 83, 83a, 90, 102, 106
, 81, 91, 102, 106
with regards to their respective reference type.
The second study, which has consisted in a random and
lind experiment, was performed on a representative col-
ection of clinical samples obtained from women attending
he cervical screening program of IPOCFG, EPE. Of the
0 cervical samples analyzed, HPV DNA was detected in
6 cases (3/10 normal samples, 3/10 low grade-lesions, 5/5
igh grade-lesions and 5/5 carcinoma samples). Correspond-
ng MY09/11 PCR products were subsequently genotyped
sing both RFLP analysis and sequencing. Table 4 shows the
esults obtained using each method. RFLP data consistently
atched the DNA sequencing results, with the exception of
ne single case, sample 22, in which it was impossible to
iscriminate the triple HPV infection using RFLP analysis,
ue to the complexity of the pattern obtained. Neverthe-
ess, in all other HPV-positive samples, even in the case
f multiple infections (e.g. samples 16 and 23), sequenc-
ng results confirmed RFLP genotyping. All the enzymes
ave shown a high cut efficiency and no partial diges-
ions were visualized under the RFLP conditions previously
escribed.
. Discussion
Due to differences in the oncogenic activity of HPVs, it is
mportant to detect HPV infection and to accurately identify
PV types in a simple and quick manner. This work aimed
t developing an easy, rapid and cost-effective PCR-RFLP
ssay to identify all known and unknown mucosal HPV types,
18 R.J. Nobre et al. / Journal of Clinical Virology 42 (2008) 13–21
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Fig. 2. Validation of RFLP restriction reactions on 10% polyacrylamide gel
(RFLP patterns from co-digestion of MY09/11PCR products of HPV 16
and Beta1/2 amplicon). Each restriction reaction was performed in a final
volume of 20l, using 1g of each PCR product, 20 units of each restriction
endonuclease at 37 ◦C for 1 h. Asterisks indicate fragments from Beta1/2
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omplicon restriction. Lane M1, 50 bp DNA molecular weight marker; Lane
2, 25 bp DNA molecular weight marker.
ased on the amplification of a fragment of the L1 gene using
Y09/11 primers and subsequent RFLP analysis.
In the impossibility of evaluating our method on the
ore than 290 published HPV variants, we made use of
ioinformatic tools to evaluate if a PCR-RFLP based method-
logy, using PstI, HaeIII, DdeI and RsaI restriction enzymes,
llowed discrimination of all individual HPV types. For that
urpose, an extensive in silico analysis of all different DNA
equences of the HPV L1 gene, corresponding to 49 mucosal
PV types, was performed for PstI, HaeIII, DdeI and RsaI
estriction sites. Of 296 HPV variants analyzed, only 23
howed a different set of RFLP patterns when compared
ith their reference type. Moreover, these 23 variants pre-
ented sets of RFLP patterns that were distinct from all the
ther types, thus not affecting the individual identification
f mucosal HPV types. The bioinformatic results have con-
rmed that each HPV type had a specific set of PstI, HaeIII,
deI and RsaI-RFLP patterns, which were not shared by
ny other HPV type and could be clearly identified by visual
iscrimination on 10% polyacrylamide gels.In summary, the herein described PCR-RFLP based
ethod permits discrimination of all known mucosal HPV
ypes (49 HPV types and 2 subtypes). This range of HPV
dentification largely exceeds the number of types character-
e
s
t
s
ig. 1. Algorithm for mucosal HPV typing after RFLP analysis of MY09/11 amplic
ach box represents a restriction reaction using a specific enzyme. Draw lines ( ) re
ines (- - -) represent the possible results when digestion occurs. In two particular
esults when digestion originates an RFLP-fragment larger than 420 bp. The HPV ty
ccurrence of PstI, HaeIII, DdeI and RsaI restriction reactions and (2) subsequent c
xpected sizes (in brackets) defined for each HPV type by in silico analysis. In ca
wo or more HPVs present similar RsaI-RFLP patterns (groups A, D, E, F, G, I), H
btained by DdeI or HaeIII restriction digestion (“confirmation pattern”).l Virology 42 (2008) 13–21 19
zed by commercial assays currently available or by any other
enotyping methodology based on RFLP analysis (Bernard
t al., 1994; Pizzighella et al., 1995; Patti et al., 2002; Naqvi
t al., 2004; Santiago et al., 2006).
A RFLP assay was recently reported that uses a single
estriction enzyme (HpyCH4V) to type 39 mucosal HPVs
Santiago et al., 2006). Although an effective discrimination
etween high- and low-risk types was achieved with this
nzyme, it did not allow an individualized identification of
ll HPV types, as some HPV types show the same HpyCH4V
FLP pattern (HPV 11 and 30; and HPV 44 and 55, for
nstance). Moreover, using HpyCH4V, several HPV types
HPV 18 and 68, HPV 18 and 70, HPV 18 and 42, HPV 31
nd 58, HPV 33 and 13, HPV 51 and 83, HPV 56 and 11,
PV 58 and 62, HPV 82 and 53, HPV 6 and 64, HPV 61
nd 84) were indistinguishable on common, non-expensive
garose or polyacrylamide gels, because the size of their
pyCH4V restriction fragments differed in less than 9 bp.
ompared to this method, our PCR-RFLP assay requires
ubstantially less sophisticated equipment in the analysis of
FLP patterns and may thus be more adequate in settings of
oor economical resources.
In order to minimize errors and avoid time consuming
rocedures associated with the complexity of visual discrim-
nation, in polyacrylamide gels, of RFLP patterns of the
ssays previously reported (Bernard et al., 1994; Santiago
t al., 2006), we have developed an original genotyping algo-
ithm to rapidly identify HPV types (Fig. 1). This algorithm
llows ready identification of HPV types in two easy steps:
1) sequential analysis of the occurrence/non-occurrence of
stI, HaeIII, DdeI and RsaI restriction reactions; and (2) sub-
equent comparison of the restriction fragments obtained in
saI digestion with the expected sizes defined for each HPV
ype. Finally, when a HPV type is identified, it is possible
o confirm it, comparing all the RFLP-patterns obtained with
ata described in Table 2.
In addition to bioinformatics studies, the reliability of
ur method and the applicability of this new HPV geno-
yping algorithm were successfully confirmed in two sets of
xperiments, which were carried out on already pre-selected
PV-positive clinical samples and on a representative col-
ection of unselected clinical samples. One limitation has
ome out of these studies. Our RFLP methodology is less
fficient when multiple HPV genotypes are present in the
ame sample. In the case of multiple infections, RFLP pat-
erns are often very complex and the resolution of fragment
izes may not allow the use of the HPV algorithm in the
ons using PstI, HaeIII, DdeI, and RsaI restriction enzymes. In the algorithm,
present the possible results when digestion does not occur, whereas dashed
situations (designated by 1 and 2), draw lines also represent the possible
pe is identified in two easy steps: (1) sequential analysis of occurrence/non-
omparison of the restriction fragments obtained by RsaI digestion with the
ses in which RsaI digestion does not occur (groups B, C and H), or when
PV type can be identified by comparison of the restriction fragment sizes
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Fig. 3. RFLP patterns of MY09/11 PCR products of HPV 16, 58 and 102. 1g of MY09/11 PCR products were mixed in a total volume of 20l with 10 units
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Af the PstI, HaeIII, DdeI, and RsaI at 37 C for 1 h. The digested and undig
eparated on 10% polyacrylamide gels, stained with Gelstar. RFLP patter
DQ080083). Lane M1, 50 bp DNA molecular weight marker; Lane P, undig
arker.
dentification of genotypes involved. Thus, the efficacy of
ur method may be improved through its incorporation in
multi-methodology strategy. Taking this into account, the
erein described assay can be used as a first-line genotyping
ethod to determine the HPV genotype in single infections
or even to discriminate between single and multiple infec-
ions), while reverse hybridization analysis may be used as
omplementary method, when unknown or complex RFLP
atterns are visualized.
The reproducibility and sensitivity of the MY09/11 ampli-
cation system were recently improved by the development
f the new primer set PGMY09/11 (Gravitt et al., 2000).
his system consists in a set of 5 upstream oligonucleotides
PGMY11 primer pool) and a set of 13 downstream oligonu-
leotides (PGMY09 primer pool), which bind to the same
egion of MY09 and MY11 primer, respectively. This new
rimer system increases the efficiency of the amplifica-
ion of some HPV types and appears to be more sensitive
han MY09/11 primers (Coutle´e et al., 2002; Giovanelli et
i
f
p
d
able 4
omparative genotyping results of HPV-positive clinical samples using RFLP anal
ample Diagnosis HPV typing
RFLP analysis res
3 Normal S–HPV 16
7 Normal S–HPV 6
8 Normal S–HPV 67
2 Low-grade lesion S–HPV 62
3 Low-grade lesion S–HPV 6
6 Low-grade lesion M–HPV 53 + 84
1 High-grade lesion S–HPV 58 (a vari
2 High-grade lesion M–*
3 High-grade lesion M–HPV 30 + 56
4 High-grade lesion S–HPV 31
5 High-grade lesion S–HPV 31
6 Carcinoma S–HPV 16
7 Carcinoma S–HPV 16
8 Carcinoma S–HPV 33
9 Carcinoma S–HPV 18
0 Carcinoma S–HPV 58 (a vari
ccession numbers of DNA sequences analyzed are given in brackets. Letters S an
* Types could not be differentiated.CR products and DNA molecular weight markers were electrophoretically
(a) HPV 16 (U89348), (b) a variant of HPV 58 (U45929), (c) HPV 102
Y09/11 PCR amplicon (≈450 bp); Lane M2, 25 bp DNA molecular weight
l., 2004). Bioinformatic analysis suggests that our HPV
yping methodology can also incorporate the PGMY sys-
em, as it is based on the same primer binding regions
sed by MY primers. Although 2 of 18 PGMY primers are
wo bases shorter than MY primers, this difference is not
ignificant and does not alter the herein described RFLP
atterns.
In conclusion, our approach offers significant advan-
ages, not only over the PCR-RFLP techniques previously
escribed, but also over other currently available HPV typ-
ng assays (like hybridization with type-specific probes,
ype-specific PCR, microarray methodologies, or any of the
ommercial platforms): (a) it detects a higher number of
ucosal HPV types (49 HPV types and 2 HPV subtypes);
b) it allows detection of unknown HPV types; and (c) it
s financially advantageous, and therefore particularly suited
or routine HPV detection and identification in settings of
oor financial resources, like cervical screening programs in
eveloping countries.
ysis and DNA sequencing/cloning analysis of MY09/11 PCR products
ults DNA sequencing and cloning results
S–HPV 16 (U89348)
S–HPV 6 (S73503)
S–HPV 67 (U12492)
S–HPV 62 (U12499)
S–HPV 6 (S73503)
M–HPV 53 (X74482) + 84 (U12490)
ant) S–HPV 58 (U45929)
M–HPV 16 (U89348) + 33 (U45896) + 6 (S73503)
M–HPV 30 (X74474) + 56 (X74483)
S–HPV 31 (AJ831566)
S–HPV 31 (AJ831566)
S–HPV 16 (U89348)
S–HPV 16 (U89348)
S–HPV 33 (U45896)
S–HPV 18 (X05015)
ant) S–HPV 58 (U45929)
d M indicate single and multiple infections, respectively.
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